 The aim of the study is to examine whether tamoxifen-treated Israeli breast cancer patients who are CYP2D6 poor metabolizers CYP2D644 genotype are at higher cancer relapse risk during 2.5-5-year follow-up period from initial diagnosis and primary treatment. 